Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) Net Margin (2016 - 2025)

Celldex Therapeutics has reported Net Margin over the past 16 years, most recently at 67204.13% for Q4 2025.

  • Quarterly results put Net Margin at 67204.13% for Q4 2025, down 6319877.0% from a year ago — trailing twelve months through Dec 2025 was 16737.45% (down 1448910.0% YoY), and the annual figure for FY2025 was 16748.03%, down 1449927.0%.
  • Net Margin for Q4 2025 was 67204.13% at Celldex Therapeutics, down from 7753.42% in the prior quarter.
  • Over the last five years, Net Margin for CLDX hit a ceiling of 384.28% in Q2 2021 and a floor of 67204.13% in Q4 2025.
  • Median Net Margin over the past 5 years was 6032.34% (2021), compared with a mean of 10222.85%.
  • Peak annual rise in Net Margin hit 1328976bps in 2025, while the deepest fall reached -6319877bps in 2025.
  • Celldex Therapeutics' Net Margin stood at 6032.34% in 2021, then soared by 73bps to 1642.1% in 2022, then soared by 36bps to 1048.32% in 2023, then tumbled by -282bps to 4005.36% in 2024, then tumbled by -1578bps to 67204.13% in 2025.
  • The last three reported values for Net Margin were 67204.13% (Q4 2025), 7753.42% (Q2 2025), and 7741.01% (Q1 2025) per Business Quant data.